1. Home
  2. WSHP vs RNTX Comparison

WSHP vs RNTX Comparison

Compare WSHP & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WSHP

WeShop Holdings Limited Class A Ordinary Shares

N/A

Current Price

$5.50

Market Cap

75.7M

Sector

N/A

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.88

Market Cap

80.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WSHP
RNTX
Founded
2021
2001
Country
British Virgin Islands
United States
Employees
20
10
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.7M
80.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WSHP
RNTX
Price
$5.50
$0.88
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
48.5K
515.7K
Earning Date
01-01-0001
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.95
$0.86
52 Week High
$250.00
$2.18

Technical Indicators

Market Signals
Indicator
WSHP
RNTX
Relative Strength Index (RSI) 40.17 35.70
Support Level $5.05 N/A
Resistance Level $7.50 $1.33
Average True Range (ATR) 0.54 0.08
MACD 0.07 0.00
Stochastic Oscillator 19.36 14.70

Price Performance

Historical Comparison
WSHP
RNTX

About WSHP WeShop Holdings Limited Class A Ordinary Shares

WeShop Holdings Ltd is a community owned social commerce platform offering shoppers shares in the company every time customers make a purchase, recommend a product or refer a new member. WeShop earns revenues from advertising on their platform and commissions on the sales through the platform.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: